WVU Medicine St. Joseph’s Hospital is proud to announce the addition of two cutting-edge imaging services: PET/CT and ...

In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.

UCLA Health’s Outpatient Theranostics Center allows clinicians to treat up to 16 patients per day with Pluvicto and other ...

Two abstracts on Clarity’s diagnostic COBRA and CLARIFY trials with 64Cu-SAR-bisPSMA have been accepted for presentation at the American Society of Clinical Oncology Genitourinary Cancers Symposium ...

The FDA granted fast track designation to 64Cu-SAR-bisPSMA for PET imaging of PSMA-positive prostate cancer lesions in ...

Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to ...

Clarity Pharmaceuticals (ASX: CU6) ('Clarity' or 'Company'), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...

Clarity Pharmaceuticals (ASX:CU6) has seen the U.S. FDA fast-track its prostate cancer imaging compound for use in PET scans on patients with recurring prostate cancer. The stock jumped 4% in the ...

These services include specialized options tailored to various cancer types. The PSMA PET CT scan is designed for prostate cancer detection, while the DOTA PET CT scan aids in identifying ...

PSMA PET scans enable precise detection of prostate cancer even in its earliest stages, improving diagnostic accuracy and enabling timely interventions.

Telix Pharma’s prostate cancer PET1 imaging agent, Illuccix receives European marketing approval: Melbourne, Australia Saturday, January 18, 2025, 10:00 Hrs [IST] Telix Pharmace ...